

Form PTO-1595 (Rev. 07/05)
OMB No. 0651-0027 (exp. 6/30/2008)U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

Hybridon, Inc.

Additional name(s) of conveying party(ies) attached? Yes No**2. Name and address of receiving party(ies)**Name: Idera Pharmaceuticals, Inc.

Internal Address: _____

Street Address: 167 Sidney STCity: CambridgeState: MassachusettsCountry: USAZip: 02139Additional name(s) & address(es) attached? Yes No**3. Nature of conveyance/Execution Date(s):**Execution Date(s) September 12, 2005

- Assignment Merger
 Security Agreement Change of Name
 Joint Research Agreement
 Government Interest Assignment
 Executive Order 9424, Confirmatory License
 Other _____

4. Application or patent number(s): This document is being filed together with a new application.

A. Patent Application No.(s)

11/174,002

B. Patent No.(s)

Additional numbers attached? Yes No**5. Name and address to whom correspondence concerning document should be mailed:**Name: Joseph C. ZuccheroInternal Address: Wood, Phillips, Katz, Clark & MortimerStreet Address: 500 West Madison StreetSuite 3800City: ChicagoState: IllinoisZip: 60661Phone Number: 312.876.2124Fax Number: 312.876.2020Email Address: jczucchero@woodphillips.com**6. Total number of applications and patents involved: 1****7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00**

- Authorized to be charged by credit card
 Authorized to be charged to deposit account
 Enclosed
 None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____

Expiration Date _____

b. Deposit Account Number 23-0785Authorized User Name Joseph C. Zucchero**9. Signature:**/Joseph C. Zucchero/March 29, 2010

Signature

Date

Joseph C. Zucchero

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

4

Documents to be recorded (including cover sheet) should be faxed to (671) 273-0140, or mailed to:
 Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1460, Alexandria, V.A. 22313-1450

PATENT

REEL: 024156 FRAME: 0357


700433183

CH \$40.00 230785 11174002

To Whom It May Concern:

On this 19th day of April, 2006, I certify that the attached document is a true, exact, complete, and unaltered copy made by me of the Certificate of Ownership and Merger Merging Idera Pharmaceuticals, Inc. (a Delaware Corporation) into Hybridon, Inc. (a Delaware Corporation), presented to me by an Officer of Idera Pharmaceuticals, Inc..

(Official Seal)



Adrienne Drago SA

Notary Signature

CERTIFICATE OF OWNERSHIP AND MERGER**MERGING****IDERA PHARMACEUTICALS, INC.**
(a Delaware corporation)**INTO****HYBRIDON, INC.**
(a Delaware corporation)

Pursuant to Section 253 of the General Corporation Law of the State of Delaware, Hybridon, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

FIRST: That the Corporation was incorporated on May 25, 1989, pursuant to the General Corporation Law of the State of Delaware.

SECOND: That the Corporation owns all of the outstanding shares of the capital stock of Idera Pharmaceuticals, Inc., a corporation incorporated on August 24, 2005, pursuant to the General Corporation Law of the State of Delaware (the "Subsidiary").

THIRD: That on September 9, 2005, the Board of Directors of the Corporation, acting by written consent in accordance with Section 141(f) of the General Corporation Law of the State of Delaware, duly adopted the following resolutions and determined to merge the Subsidiary into the Corporation and change the Corporation's corporate name to "Idera Pharmaceuticals, Inc." on the conditions set forth in such resolutions:

RESOLVED: That, the Corporation shall, pursuant to Section 253 of the Delaware Code, merge into itself Idera Pharmaceuticals, Inc., a wholly owned subsidiary of the Corporation (the "Subsidiary"), and shall assume all of the Subsidiary's liabilities and obligations (the "Merger"); and that upon the effectiveness of the Merger, the Corporation's corporate name shall be changed to "Idera Pharmaceuticals, Inc."

RESOLVED: That the Corporation, as the sole stockholder of the Subsidiary, be and hereby is authorized to take such actions as are necessary or appropriate to effect the Merger.

RESOLVED: That the Chief Executive Officer and the Chief Financial Officer of the Corporation (the "Proper Officers") be, and either acting singly, hereby is authorized and directed in the name and on behalf of the Corporation to prepare, execute and file with the Secretary of State of the State of Delaware a Certificate of Ownership and Merger setting forth a copy of the resolutions to merge the Subsidiary into the Corporation and to assume the liabilities and obligations of said Subsidiary and to change the Corporation's corporate name to "Idera Pharmaceuticals, Inc." upon the effectiveness of the Merger; and that the execution and filing thereof be conclusive evidence of such approval and the authorization therefor by the Board of Directors of the Corporation.

FOURTH: That the Merger of Subsidiary into the Corporation be effective as of September 12, 2005 at 4:01 p.m. (ET).

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12th day of September, 2005.

HYBRIDON, INC.

By: 

Name: Sudhir Agrawal

Title: Chief Executive Officer and
President

Intellectual Property Law
500 West Madison Street
Suite 3800
Chicago, Illinois 60661-2562
T (312) 876.1800
F (312) 876.2020
www.woodphillips.com



Date: March 29, 2010

To: Assignment Division
USPTO
571.273.0140

From: Joseph C. Zucchero
Direct Phone (312) 876-2124
E-Mail jczuchero@woodphillips.com

Pages including this cover sheet: 5 Serial No. 11/174,002

**If you do not receive all of the enclosed pages,
please contact Rachel Burke at 312.876.2127**

THE MESSAGE TRANSMITTED UNDER THIS COVER IS INTENDED FOR THE NAMED RECIPIENT ONLY, AND MAY CONTAIN BUSINESS CONFIDENTIAL INFORMATION, OR INFORMATION SUBJECT TO ATTORNEY-CLIENT PRIVILEGE, OR ATTORNEY WORK PRODUCT IMMUNITY. IN THE EVENT THIS MESSAGE IS RECEIVED AT A LOCATION WHERE IT CANNOT BE CONVEYED TO THE NAMED RECIPIENT, KINDLY NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE/FACSIMILE (IF LONG DISTANCE, PLEASE CALL COLLECT), AND RETURN THE RECEIVED MESSAGE TO US BY MAIL.